XTL BIOPHARMACEUTICALS LTD.

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
Directors and Senior Management
The following sets forth information with respect to our directors and executive officers as of February 29, 2008. Except as noted, the business
address for each of the following is 711 Executive Blvd., Suite Q, Valley Cottage, NY 10989, USA.
Name Age Position
Michael S. Weiss 42 Chairman of the Board of Directors
William J. Kennedy, Ph.D 63 Non Executive Director
Ido Seltenreich (1) 36 Non Executive and External Director
Vered Shany, D.M.D (1) 43 Non Executive and External Director
Ben Zion Weiner, Ph.D (1) 63 Non Executive Director
Ron Bentsur 42 Chief Executive Officer
Bill Kessler (1) 42 Director of Finance
(1) Business address is Kiryat Weizmann Science Park, Building 3, POB 370, Rehovot 76100, Israel.
Michael S. Weiss has served as a director of our company since November 2004, and was appointed interim Chairman of the Board in March
2005 and Chairman of the Board in August 2005. Mr. Weiss is currently the Chairman and CEO of Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX). Prior to that, from 1999-2002, Mr. Weiss served as CEO and Chairman, and later as the Executive Chairman, of ACCESS Oncology, Inc. a
private biotechnology company subsequently acquired by Keryx. Prior to that, Mr. Weiss served as Senior Managing Director of Paramount Capital,
Inc., a broker-dealer registered with the National Association of Securities Dealers. From 1991-1993, Mr. Weiss was an attorney at Cravath, Swaine &
Moore. Mr. Weiss received his B.A., magna cum laude from State University of New York at Albany and was awarded a Juris Doctorate degree from
Columbia University Law School.
William J. Kennedy has served as a director of our company since February 2005. Dr. Kennedy retired as Vice President, Drug Regulatory
Affairs, for Zeneca Pharmaceuticals Group in October 1999, and since that time has served as a regulatory consultant to the pharmaceutical industry.
Prior to joining Zeneca Pharmaceuticals in 1986, Dr. Kennedy worked in regulatory affairs at G.D. Searle & Co., Kalipharma Inc., Berlex
Laboratories, Inc. and Pfizer Pharmaceuticals, Inc. Dr. Kennedy earned a B.S. from Siena College, a M.A. from Clark University and a Ph.D in
Pharmacology from SUNY, Buffalo. Prior to joining the industry in 1977, he was an Associate Research Professor at Yale University conducting
research in Molecular Biology and Recombinant DNA.
Ido Seltenreich has served as a director of our company since August 2005. Mr. Seltenreich is currently the financial representative in
Bulgaria, of Cinema City International N.V., or CCI, (Polish Stock Exchange - CCIINT) and of OCIF Investment & Development LTD (TASE -
OCIF). Prior to that, from October 1999 to September 2006, Mr. Seltenreich was the representative of CCI in the Czech Republic, for which he had
served as the Managing and Financing Director. From July 2003 to August 2005, Mr. Seltenreich also served as a member of the Board of Directors of
an intragroup company of CCI, a development company that operated in the Bulgarian market. Prior to that, from 1996-1999, Mr. Seltenreich worked
at Luboshits Kasirer, a member of Ernst & Young. Mr. Seltenreich received his B.A. in economics and accounting from Haifa University and has an
Israeli CPA license.
Vered Shany has served as a director of our company since August 2005. Since September 2006, Dr. Shany has served as the founder,
Chairman and CEO of Lotus Bio Inc., a private medical diagnostics company. Since March 2002, Dr. Shany has managed Tashik Consultants,
providing strategic consulting and corporate analysis for Israeli and international corporations and investment management in life sciences companies.
Previously, Dr. Shany served as managing director of Up-Tech Ventures Ltd, a subsidiary of the Africa-Israel Investments Group from May 2000 to
March 2002, as a member of the Board of Directors of the Weizmann Science Park Incubator from May 2000 to March 2002, and as vice president of
marketing for Arad Technological Incubator from 1995 to 1999. Dr. Shany is currently an external director of Capital Point Ltd., since August 2006,
and in Simigon Ltd., since September 2006. Dr. Shany served as an external director in Lahak Mutual Funds of Bank Hapoalim, from October 2000 to
September 2006, and in SFKT - Shrem Fudim Kellner Technologies, from September 2000 to September 2006. Dr. Shany holds an M.A. in business
administration from Heriot - Watt University, Edinburgh Business School, and she completed her D.M.D., Doctor of Medical Dentistry, and her
B.Med.Sc, from Hebrew University of Jerusalem.
39